Study: Bone drug cuts risk of breast cancer relapse

06/1/2008 | USA Today · Wall Street Journal, The

Zometa, Novartis AG's bone-building drug, lowered the chances of breast cancer recurrence by 35% in premenopausal women with early-stage, hormone-sensitive breast cancer when combined with hormone therapy, a study of more than 1,800 patients found. The findings also showed that 9% of those who did not take Zometa in addition to hormone treatments either died or experienced a recurrence, compared with 6% of those who received the drug.

View Full Article in:

USA Today · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN